ArticleFrontiers in nutrition2025
Association of SII and SIRI with incidence of cardiovascular disease in cardiovascular-kidney-metabolic syndrome: a prospective cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Association of sarcopenic obesity with advanced cardiovascular-kidney-metabolic syndrome and incident cardiovascular disease: a longitudinal and cross-sectional study.Diabetology & metabolic syndrome · 2026Article
- Mitochondrial Dysfunction at the Intersection of CKM Syndrome: Molecular Mechanisms and Path-to-Target Therapies.International journal of molecular sciences · 2026Review
- Joint association of estimated glucose disposal rate and systemic inflammation response index with mortality in metabolic-dysfunction associated steatotic liver disease: evidence from two cohort studies.Cardiovascular diabetology · 2026Observational
- Emerging multidimensional biomarker system for cardiovascular-kidney-metabolic syndrome: from multi-omics integration to clinical artificial intelligence.Cardiovascular diabetology · 2026Review
- Association between systemic inflammation response index and risk of major adverse cardiovascular events in adults with and without metabolic syndrome: a prospective cohort study in Shanghai, Pudong.Frontiers in endocrinology · 2026Article
- Association and Predictive Value of C-Reactive Protein-Lymphocyte-Albumin (CALLY) Index with Cardiovascular Disease in Patients with Cardiovascular-Kidney-Metabolic Syndrome Stage 3.International journal of general medicine · 2026Article
- Association between systemic immune-inflammation index and all-cause mortality in ischemic stroke patients.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The relationship between systemic immune-inflammation biomarkers, the Systemic Immune-Inflammation Index (SII) and the Systemic Inflammation Response Index (SIRI), and cardiovascular disease (CVD) in cardiovascular-kidney-metabolic (CKM) syndrome remains unclear. Methods: Individuals with CKM syndrome at stages 0-3 from UK Biobank were included in this study. Cox regression models were used to assess the association of SII and SIRI with incidence of CVD. Restricted cubic spline (RCS) models were applied to examine nonlinear longitudinal associations. Subgroup stratified by CKM stages were analyzed. Results: A total of 301,631 participants with CKM stages 0 (14.1%), 1 (19.4%), 2 (56.7%), and 3 (9.8%) were included in this study. During a median follow-up of 13.0 years, CVD incidence occurred in 35,782 (11.86%) participants. After adjustment, the elevated SII (HR: 1.07, 95% CI: 1.05-1.10, Conclusion: As the main systemic immune-inflammation biomarkers, the elevated SII and SIRI in CKM syndrome were significantly associated with increased risk of CVD incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.